Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3047)
All Articles published online
|
May 21, 2005 (publication date) through Dec 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Li WD, Wang MJ, Ding F, Yin DL, Liu ZH. Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells. World J Gastroenterol 2005; 11(19): 2927-2931 [PMID: 15902730 DOI: 10.3748/wjg.v11.i19.2927] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i19/2927.htm |
| Number | Citing Articles |
| 1 |
Dingding Shi, Steven R. Grossman. Ubiquitin becomes ubiquitous in cancer. Cancer Biology & Therapy 2010; 10(8): 737 doi: 10.4161/cbt.10.8.13417
|
| 2 |
Sudharsana Rao Ande, Junjie Chen, Subbareddy Maddika. The ubiquitin pathway: An emerging drug target in cancer therapy. European Journal of Pharmacology 2009; 625(1-3): 199 doi: 10.1016/j.ejphar.2009.08.042
|
| 3 |
Lu Deng, Tong Meng, Lei Chen, Wenyi Wei, Ping Wang. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-0107-0
|
| 4 |
Yan Li, Robert C.G. Martin. Apoptosis in Carcinogenesis and Chemotherapy. 2009; : 127 doi: 10.1007/978-1-4020-9597-9_6
|
| 5 |
Gabriel LaPlante, Wei Zhang. Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors. Cancers 2021; 13(12): 3079 doi: 10.3390/cancers13123079
|
| 6 |
Jason A. Clement, Jirouta Kitagaki, Yili Yang, Carrie J. Saucedo, Barry R. O’Keefe, Allan M. Weissman, Tawnya C. McKee, James B. McMahon. Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53. Bioorganic & Medicinal Chemistry 2008; 16(23): 10022 doi: 10.1016/j.bmc.2008.10.024
|
| 7 |
Peter M. Fischer. Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53–HDM2 Protein–Protein Interaction. International Journal of Peptide Research and Therapeutics 2006; 12(1): 3 doi: 10.1007/s10989-006-9016-5
|
| 8 |
Gianluca Bossi, Ada Sacchi. Restoration of wild‐type p53 function in human cancer: Relevance for tumor therapy. Head & Neck 2007; 29(3): 272 doi: 10.1002/hed.20529
|
| 9 |
A. M. Weissman, Y. Yang, J. Kitagaki, C. A. Sasiela, J. A. Beutler, B. R. O'Keefe. The Ubiquitin System in Health and Disease. Ernst Schering Foundation Symposium Proceedings 2008; : 171 doi: 10.1007/2789_2008_108
|
| 10 |
Jirouta Kitagaki, Keli K. Agama, Yves Pommier, Yili Yang, Allan M. Weissman. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Molecular Cancer Therapeutics 2008; 7(8): 2445 doi: 10.1158/1535-7163.MCT-08-0063
|
| 11 |
Ainsley Mike Antao, Apoorvi Tyagi, Kye-Seong Kim, Suresh Ramakrishna. Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers 2020; 12(6): 1579 doi: 10.3390/cancers12061579
|
| 12 |
Tadashi Hirata, Young-Man Cho, Isamu Suzuki, Takeshi Toyoda, Jun-ichi Akagi, Yasushi Nakamura, Satoshi Numazawa, Kumiko Ogawa. 4-Methylthio-3-butenyl isothiocyanate (MTBITC) induced apoptotic cell death and G2/M cell cycle arrest via ROS production in human esophageal epithelial cancer cells. The Journal of Toxicological Sciences 2019; 44(2): 73 doi: 10.2131/jts.44.73
|